Total Funding
23
49
Total FundingSeries C raised
Growth Score 23 in past quarter
-4 pts
Heat Score 49 in past quarter
-9 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
151599
Recomgen Biotech engages in R&D, production and sales of drugs.
About the Company
Recomgen Biotech is an innovative biopharmaceutical company that focuses on large-scale serum-free continuous animal cell culture technology and the R&D of new biological drugs. Recomgen Biotech is working on developing rhTNK-tPA, a generation-specific thrombolytic drug that can be injected intravenously in a single dose, making it convenient
for emergency treatment and out-of-hospital thrombolysis as needed. It improves the treatment rate, clinical benefit, and personal and societal medical burdens in patients with acute myocardial infarction who received thrombolytic therapy.